Condition: Fragile X Syndrome (FXS) · Fragile X Syndrome · Sponsor: Connecta Therapeutics, S.L.
The purpose of this Phase IIa study is to evaluate the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome.
This description comes directly from the study's public registry record.
Josep Prous, PhD · (+34) 934034509 · clinicaltrials@connectatherapeutics.com
Always discuss trial participation with your own doctor first.
| Hospital del Mar Medical Research Institute | Barcelona, Barcelona, Spain | Recruiting |
| Consorci Corporació Sanitaria Parc Taulí. Institut Investigació i Innovació Parc Taulí (I3PT) | Sabadell, Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07654114